Lot-to-lot consistency, immunogenicity, and safety of a 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy adults aged 40–65 years: A randomized, double-blind, controlled, phase IV clinical trial
Yunong Zhang, Gang Shi, Siliang Zhou, Weimin Zhao et autres
cn, tw (code pays fourni par la source)